Related Experiment Video
Updated: May 2, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Pegylated interferons: a nurses' review of a novel multiple sclerosis therapy
Anne Howley1, Marcelo Kremenchutzky
1Questions or comments about this article may be directed to Anne Howley, RN, at anne.howley@lhsc.on.ca. She is a Research Coordinator at the Multiple Sclerosis Clinic, London Health Sciences Centre, London, Ontario, Canada. Marcelo Kremenchutzky, MD, is the Director of the Multiple Sclerosis Clinic and a Consultant Neurologist at London Health Sciences Centre and an Associate Professor of Neurology at Western University, London, Ontario, Canada.
Abstract:
Most multiple sclerosis (MS) therapies are injectable drugs, and the frequency of injections has been shown to be inversely proportional to overall compliance. One method of improving therapeutic compliance and thus clinical outcomes is to develop medications that require less frequent dosing. One of the most promising modification techniques to extend the bioavailability of a drug is poly(ethylene glycol) conjugation (pegylation), which increases the size of a molecule by attaching polyethylene glycol moieties to the parent compound, resulting in slower clearance and metabolism. This approach has been used to improve the efficacy of a number of therapeutic molecules, including interferons. Peginterferon beta-1a, a pegylated form of interferon beta-1a, is currently in phase III clinical trials for relapsing MS and has the potential to improve patient compliance by reducing the number of injections while maintaining clinical efficacy. The role of nurses in educating patients about the effective use of this new MS therapy is discussed.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Multiple Sclerosis l: Introduction
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Peripheral Artery Disease IV: Nursing Management
Nephrotic Syndrome III : Nursing Management
Myocarditis IV: Nursing Management

